The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials
Open accessAbstract
Importance: Accumulation of disability in multiple sclerosis may occur as relapse-associated worsening (RAW) or steady progression independent of relapse activity (PIRA), with PIRA regarded as a feature of primary and secondary progressive multiple sclerosis. Objective: To investigate the contributions of relapse-associated worsening vs relapse-independent progression to overall confirmed disability accumulation (CDA) and assess respective baseline prognostic factors and outcomes of 2 treatments. Design, Setting, and Participants: Analyses occurred from July 2015 to February 2020 on pooled data from the intention-to-treat population of 2 identical, phase 3, multicenter, double-blind, double-dummy, parallel-group randomized clinical trials (OPERA I and II) conducted between August 2011 and April 2015. In the trials, patients with relapsing multiple sclerosis (RMS), diagnosed using the 2010 revised McDonald criteria, were randomized from 307 trial sites in 56 countries; resulting data were analyzed in the pooled data set. Interventions: Participants were randomized 1:1 to receive 600 mg of ocrelizumab by intravenous infusion every 24 weeks or subcutaneous interferon β-1a 3 times a week at a dose of 44 μg throughout a 96-week treatment period. Main Outcomes and Measures: Confirmed disability accumulation was defined by an increase in 1 or more of 3 measures (Expanded Disability Status Scale, timed 25-ft walk, or 9-hole peg test), confirmed after 3 or 6 months, and classified per temporal association with confirmed clinical relapses (PIRA or RAW). Results: In the pooled OPERA I and II population (1656 of 2096 eligible participants), baseline demographics and disease characteristics were similar for patients randomized to interferon β-1a vs ocrelizumab (mean [SD] age, 37.2 [9.2] vs 37.1 [9.2] years; 552 [66.6%] vs 541 women [65.4%]). After 96 weeks, 12-week composite CDA had occurred in 223 (29.6% by Kaplan-Meier estimate) randomized to interferon β-1a and 167 (21.1%) randomized to ocrelizumab; 24-week composite CDA had occurred in 170 (22.7%) taking interferon β-1a and 129 (16.2%) taking ocrelizumab. The PIRA events were the main contributors to 12-week and 24-week composite CDA after 96 weeks in patients treated with interferon β-1a (174 of 223 [78.0%] and 137 of 170 [80.6%], respectively) and ocrelizumab (147 of 167 [88.0%] and 115 of 129 [89.1%], respectively); a minority had CDA explained by RAW events (69 of 390 [17.7%] and 52 of 299 [17.4%], respectively). Very few patients with composite CDA experienced both RAW and PIRA events (17 of 390 [4.4%] for 12-week and 15 of 299 [5.0%] for 24-week composite CDA). Ocrelizumab (vs interferon β-1a) was associated with reduced risk of composite CDA (hazard ratio [HR], 0.67) and confirmed PIRA (HR, 0.78) and RAW (HR, 0.47) events. Conclusions and Relevance: Most disability accumulation in RMS is not associated with overt relapses. This indicates an underlying progression in this typical RMS population and challenges the current clinical distinction of relapsing and progressive forms of multiple sclerosis. Ocrelizumab was superior to interferon β-1a in preventing both RAW and PIRA. Trial Registration: ClinicalTrials.gov Identifiers: OPERA I (NCT01247324) and OPERA II (NCT01412333).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
Self-citationAxonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Defining the clinical course of multiple sclerosis: The 2013 revisions
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000560 · Cited by 3,177
Self-citationOcrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H.-P., Hemmer, B., Lublin, F., Montalban, X., Rammohan, K. W., Selmaj, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1601277 · Cited by 2,021
Self-citationOcrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H.-P., Hemmer, B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606468 · Cited by 1,905
Self-citationSerum neurofilament light: a biomarker of neuronal damage in multiple sclerosis
Disanto, G., Barro, C., Benkert, P., Naegelin, Y., Schädelin, S., Giardiello, A., Zecca, C., Blennow, K., Zetterberg, H., Leppert, D., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24954 · Cited by 1,164
Self-citationBarro, C., Benkert, P., Disanto, G., Tsagkas, C., Amann, M., Naegelin, Y., Leppert, D., Gobbi, C., Granziera, C., Yaldizli, Ö., et al. (2018) · Brain · doi:10.1093/brain/awy154 · Cited by 517
Self-citationSilent progression in disease activity–free relapsing multiple sclerosis
University of California, S. F. M. T., Cree, B. A. C., Hollenbach, J. A., Bove, R., Kirkish, G., Sacco, S., Caverzasi, E., Bischof, A., Gundel, T., Zhu, A. H., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25463 · Cited by 465
Self-citationLublin, F., Miller, D. H., Freedman, M. S., Cree, B. A. C., Wolinsky, J. S., Weiner, H., Lubetzki, C., Hartung, H.-P., Montalban, X., Uitdehaag, B. M. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01314-8 · Cited by 448
Self-citationLong‐term evolution of multiple sclerosis disability in the treatment era
University of California, S. F. M. T., Cree, B. A. C., Gourraud, P., Oksenberg, J. R., Bevan, C., Crabtree‐Hartman, E., Gelfand, J. M., Goodin, D. S., Graves, J., Green, A. J., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24747 · Cited by 440
Self-citationDefining secondary progressive multiple sclerosis
Lorscheider, J., Buzzard, K., Jokubaitis, V., Spelman, T., Havrdova, E., Horakova, D., Trojano, M., Izquierdo, G., Girard, M., Duquette, P., et al. (2016) · Brain · doi:10.1093/brain/aww173 · Cited by 415
DiLillo, D. J., Hamaguchi, Y., Ueda, Y., Yang, K., Uchida, J., Haas, K. M., Kelsoe, G., & Tedder, T. F. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.1.361 · Cited by 385
B CELL IMMUNOBIOLOGY IN DISEASE: Evolving Concepts from the Clinic
Martin, F., & Chan, A. C. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090517 · Cited by 369
Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes
De Stefano, N., Giorgio, A., Battaglini, M., Rovaris, M., Sormani, M. P., Barkhof, F., Korteweg, T., Enzinger, C., Fazekas, F., Calabrese, M., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e24136 · Cited by 321
Genovese, M. C., Kaine, J. L., Lowenstein, M. B., Giudice, J. D., Baldassare, A., Schechtman, J., Fudman, E., Kohen, M., Gujrathi, S., Trapp, R. G., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23732 · Cited by 207
Predictors of long‐term disability accrual in relapse‐onset multiple sclerosis
Jokubaitis, V. G., Spelman, T., Kalincik, T., Lorscheider, J., Havrdova, E., Horakova, D., Duquette, P., Girard, M., Prat, A., Izquierdo, G., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24682 · Cited by 191
Kappos, L., Butzkueven, H., Wiendl, H., Spelman, T., Pellegrini, F., Chen, Y., Dong, Q., Koendgen, H., Belachew, S. M., Trojano, M., et al. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517709619 · Cited by 161
Self-citationCadavid, D., Cohen, J. A., Freedman, M. S., Goldman, M. D., Hartung, H.-P., Havrdová, E., Jeffery, D., Kapoor, R., Miller, A., Sellebjerg, F. T., et al. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516638941 · Cited by 152
Goodin, D. S., Traboulsee, A. L., Knappertz, V. A., Reder, A. T., Li, D., Langdon, D. W., Wolf, C., Beckmann, K., Konieczny, A., Ebers, G. C., et al. (2011) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-301178 · Cited by 100
Extensive acute axonal damage in pediatric multiple sclerosis lesions
Pfeifenbring, S., Bunyan, R. F., Metz, I., Röver, C., Huppke, P., Gärtner, J., Lucchinetti, C. F., & Brück, W. (2015) · Annals of Neurology · doi:10.1002/ana.24364 · Cited by 99
Havrdová, E., Arnold, D. L., Bar‐Or, A., Comi, G., Hartung, H., Kappos, L., LUBLIN, F. D., Selmaj, K. W., Traboulsee, A. L., Belachew, S. M., et al. (2018) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/2055217318760642 · Cited by 60
Self-citationWorsening of disability caused by relapses in multiple sclerosis: A different approach
Koch‐Henriksen, N., Thygesen, L. C., Sørensen, P. S., & Magyari, M. (2019) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2019.04.017 · Cited by 36
Response to: Monoclonal antibodies targeting CD20
Klein, C., Lammens, A., Schäfer, W., Georges, G. J., Schwaiger, M., Mössner, E., Hopfner, K., Umaña, P., & Niederfellner, G. J. (2013) · mAbs · doi:10.4161/mabs.24108 · Cited by 14
Cited by
Treatment of Multiple Sclerosis: A Review
Hauser, S. L., & Cree, B. A. C. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.05.049 · Cited by 969
Self-citationMultiple sclerosis progression: time for a new mechanism-driven framework
Kuhlmann, T., Moccia, M., Coetzee, T., Cohen, J. A., Correale, J., Graves, J., Marrie, R. A., Montalban, X., Yong, V. W., Thompson, A. J., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00289-7 · Cited by 667
How patients with multiple sclerosis acquire disability
Lublin, F. D., Häring, D. A., Ganjgahi, H., Ocampo, A., Hatami, F., Čuklina, J., Aarden, P., Dahlke, F., Arnold, D. L., Wiendl, H., et al. (2022) · Brain · doi:10.1093/brain/awac016 · Cited by 549
“The clinical distinction of re-lapsing and progressive forms of multiple sclerosis has recently been challenged: In a study by Kappos et al. 1 including pooled data from two large phase 3 clinical trials in relapsing multiple sclerosis, most disability accumulation was not associated with overt relapses.”
InfluentialSelf-citationTur, C., Carbonell-Mirabent, P., Cobo-Calvo, Á., Otero-Romero, S., Arrambide, G., Midaglia, L., Castilló, J., Vidal-Jordana, Á., Rodríguez-Acevedo, B., Zabalza, A., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2022.4655 · Cited by 273
Smouldering multiple sclerosis: the ‘real MS’
Giovannoni, G., Popescu, V., Wuerfel, J., Hellwig, K., Iacobaeus, E., Jensen, M. B., García-Domínguez, J. M., Sousa, L., De Rossi, N., Hupperts, R., et al. (2022) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864211066751 · Cited by 271
Self-citation
Metadata
- Authors
- Kappos, L., Wolinsky, J. S., Giovannoni, G., Arnold, D. L., Wang, Q., Bernasconi, C., Model, F., Koendgen, H., Manfrini, M., Belachew, S., & Hauser, S. L.
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2020-09-01
- Volume
- 77
- Issue
- 9
- Pages
- 1132
- ISSN
- 2168-6149 (ISSN-L)
- OpenAlex
- W3033968144
- Cited by
- 658
- References
- 23
- FWCI
- 31.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.